Inhibition by bosentan, an endothelin antagonist, of the hypersensitivity to Ca2+ channel activator evoked by salt-loading in basilar artery of stroke-prone spontaneously hypertensive rats

Life Sciences

Volumn 59, Issue 16, 1996, Pages PL247-PL253

  Salomone, Salvatore ^a   Dessy, Chantal ^a   Morel, Nicole ^a   Godfraind, Théophile ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

basilar artery; Bay K 8644; bosentan; endothelin 1; stroke prone rats

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; BOSENTAN; CALCIUM CHANNEL STIMULATING AGENT; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; N(G) NITROARGININE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASILAR ARTERY; BLOOD VESSEL REACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG ANTAGONISM; HEREDITARY HYPERTENSION; HYPERSENSITIVITY; ISOLATED ARTERY; MORBIDITY; NONHUMAN; RAT; SALT INTAKE; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE;

ANIMALIA;

EID: 0030582459     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/0024-3205(96)00463-8     Document Type: Article

References (23)

1. 1. K. OKAMOTO, Y. YAMORI and A. NAGAOKA, Circ. Res. 34/35(Suppl. 1) 1143-1153 (1974).
2. 2. G. GAVIRAGHI and T. GODFRAIND, Calcium Antagonists: Pharmacology and Clinical Research. T. Godfraind, S. Govoni, R. Paoletti and P.M. Vanhoutte (Eds), 65-69, Kluwer Academic Publishers, Dordrecht, (1993).
3. 3. O. FERON, S. SALOMONE and T. GODFRAIND, Br. J. Pharmacol. 118 659-664 (1996).
4. 4. J.-P. STASCH, C. HIRTH-DIETRICH, K. FROBEL and M. WEGNER, J. Cardiovasc. Pharmacol. 26(Suppl. 3) S436-S438 (1995).
5. 5. D.B. STANIMIROVIC, N. BERTRAND, R. MCCARRON, S. UEMATSU and M. SPATZ, Acta Neurochir. Suppl. Wien. 60 71-75 (1994).
6. 6. M. CLOZEL, V. BREU, K. BURRI, J.M. CASSAL, W. FISCHLI, G.A. GRAY, G. HIRTH, B.M. LÖFFLER, M. MÜLLER, W. NEIDHART and H. RAMUZ, Nature 365 759-761 (1993).
7. 7. M. CLOZEL, V. BREU, G.A. GRAY, B. KALINA, B.M. LÖFFLER, K. BURRI, J.M. CASSAL, G. HIRTH, M. MÜLLER, W. NEIDHART and H. RAMUZ, J. Pharmacol. Exp. Ther. 270 228-235 (1994).
8. 8. T. GODFRAIND, D. MENNIG, N. MOREL and M. WIBO, J. Cardiovasc. Pharmacol. 13(Suppl.5) S112-S117 (1989).
9. 9. P. CRISTOFORI, D. MICHELI, A. TERRON and G. GAVIRAGHI, J. Cardiovasc. Pharmacol. 23(Suppl.5) S90-S93 (1994).
10. 10. M.J. MULVANY and W. HALPERN, Circ. Res. 41 19-26 (1977).
11. 11. A. MULSCH and R. BUSSE, Naunyn-Schmiedeberg's Arch Pharmacol. 341 143-147 (1990).
12. 12. N. MOREL and T. GODFRAIND, J. Cardiovasc. Pharmacol. 24 524-533 (1994).
13. 13. M. SPEDDING and C. BERG, Naunyn-Schmiedeberg's Arch Pharmacol. 328 69-75 (1984).
14. 14. M.R. LAUER, M.D. GUNN and W.T. CLUSIN, J. Physiol. 448 729-747 (1992).
15. 15. M. HORI, K. SATO, S. MIYAMOTO, H. OZAKI and H. KARAKI, Br. J. Pharmacol. 110 1527-1531 (1993).
16. 16. M.C. GONG, K. IIZUKA, G. NIXON, J.P. BROWNE, A. HALL, J.F. ECCLESTON, M. SUGAI, S. KOBAYASHI, A.V. SOMLYO and A.P. SOMLYO, Proc. Natl. Acad. Sci. USA 63 1340-1345 (1996).
17. 17. S.M. ARRIBAS, J.F. GORDON, C.J. DALY, A. DAVIDSON, A.F. DOMINICZAK and J. MCGRATH, J. Hypertension 12 1307-1325 (1994).
18. 18. X. WANG, S.A. DOUGLAS, C. LOUDEN, L.M. VICKERY-CLARK, G.Z. FEUERSTEIN and E.H. OHLSTEIN, Circ. Res. 78 322-328 (1996).
19. 19. L MORBIDELLI, C. ORLANDO, C.A. MAGGI, F. LEDDA and M. ZICHE, Am. J. Physiol. 269 H686-H695 (1995).
20. 20. U.S. SMEDA, Stroke 20 1212-1218 (1989).
21. 21. R. SUZUKI, H. MASAOKA, Y. HIRATA, F. MARUMO, E. ISOTANI and K. HlRAKAWA, J. Neurosurg. 77 96-100 (1992).
22. 22. R.N. WILLETTE, H. ZHANG, M.P. MITCHELL, C.F. SAUERMELCH, E.H. OHLSTEIN and A.C. SULPIZIO, Stroke 25 2450-2456 (1994).
23. 23. N. MOREL, P. GHISDAL and T. GODFRAIND, Endothelium Derived Hyperpolarizing Factor, 255-261, P.M. Vanhoutte (Ed), Harwood Academic Publishers, Reading, in press.